Neoadjuvant Therapy Prior to Prostatectomy - Mary-Ellen Taplin

In this conversation, Mary-Ellen Taplin reviews her work from the past nine years in the area of neoadjuvanct therapies prior to prostatectomy.  Mary-Ellen discusses how research on combining systematic therapy with prostatectomy when next generation androgen-AR axis inhibitors were developed have now lead to the launch of a large, international phase 3 trial.


Mary-Ellen Taplin, MD Chair, Executive Committee for Clinical Research Director of Clinical Research, Lank Center for Genitourinary Oncology Institute Physician, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School

Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.